Morgan Stanley raised the firm’s price target on Crinetics (CRNX) to $77 from $65 and keeps an Overweight rating on the shares. The FDA approval of Palsonify cam with a better than expected list price and “broad” label, the analyst tells investors in a research note. The firm believes the drug is positioned to address a significant unmet need for a once-daily oral option across patient segments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Trump threatens new tariffs on drugs, kitchen cabinets, trucks: Morning Buzz
- Crinetics rises 25.7%
- Crinetics rises 21.9%
- Crinetics price target raised to $62 from $58 at Baird
- Buy Rating for Crinetics Pharmaceuticals Driven by FDA Approval and Strategic Market Positioning of Palsonify